Use of the medical differential diagnosis to achieve optimal end-stage renal disease outcomes.
Compared with the general population, end-stage renal disease (ESRD) patients continue to have a higher than expected morbidity and mortality. Hypoalbuminemia, anemia, hypertension, and inadequate dialysis are all thought to contribute to the high morbidity and mortality among ESRD patients. Anemia algorithms should help to standardize the approach to anemia and the use of recombinant human erythropoietin (rHuEPO), but clinicians still must review each patient individually, searching for and treating the multitude of interrelated factors that affect rHuEPO responsiveness. Hypoalbuminemia is a very strong predictor of increased morbidity and mortality in dialysis and nondialysis patients. The causes of hypoalbuminemia are multifactorial, and diagnosis of the cause of hypoalbuminemia is usually elusive. The basis of the poorer survival in US dialysis patients remains controversial, but inadequate dialysis has been implicated. To assure adequate dialysis, the dialysis prescription must be individualized for each patient, and delivered dialysis must be routinely monitored. Hypertension is associated with left ventricular hypertrophy, which is also an important determinant of survival in ESRD patients. Hypertension should be treated in ESRD patients in conjunction with other interventions that are known to reverse left ventricular hypertrophy. Special efforts must be made in the medical management of hypoalbuminemia, anemia, hypertension, and dialysis treatment adequacy to improve survival in patients with ESRD.